{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:28Z","timestamp":1777934488042,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective trial, we analyzed data of patients with relapsed\/refractory lymphoma who received outpatient fractionated ICE between 2011-2017 at a tertiary care center. The three weekly ICE protocol consisted of: ifosfamide 1500\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      infused over 2\u2009h on days 1\u20133, carboplatin (5 AUC) on day 1, and etoposide 100\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1\u20133. Rituximab 375\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was given to patients with CD20 positive B cell Non-Hodgkin lymphoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total of 89 patients were included in this research project. Majority of patients had Hodgkin lymphoma (64%). Mean number of ICE cycles received was 2.5. Complete remission and partial remission rates for primary refractory (62.9%) and non-primary refractory (36.4%) disease were 10.5% and 26.3% versus 41.9% and 29.0% respectively. Event free survival rate was 14.5\u2009months (95% CI 7.7\u201328.0) and overall survival rate 88.7\u2009months (95% CI 48.1\u2013NR). Grade 3 hematological toxicities were documented in 19.1% of patients with 10.1% experiencing neutropenia and 9% thrombocytopenia. 5.6% had febrile neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study included, to our knowledge, the largest number of patients treated with outpatient fractionated ICE. Results demonstrated that this regimen might be a reasonable replacement for classic ICE regimen in many patients with lymphoma. It has a favorable safety profile. However, patients with primary refractory lymphomas need more effective regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220988062","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T05:37:48Z","timestamp":1611121068000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Outpatient fractionated ICE protocol in relapsed\/refractory lymphomas: Efficacy and safety"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-9342","authenticated-orcid":false,"given":"Reyad","family":"Dada","sequence":"first","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"},{"name":"College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab Mosaad","family":"Abdelghani","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"},{"name":"Medical Oncology, Cairo University, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Boubakra","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaweed","family":"Vayani","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Yousof","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"},{"name":"Radiation Oncology and Nuclear Medicine, Cairo University, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L Goldman","family":"Heaphy","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhar","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"bibr1-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"bibr2-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"bibr3-1078155220988062","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"bibr4-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00996.x"},{"key":"bibr5-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"bibr6-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"bibr7-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"bibr8-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"bibr9-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"bibr10-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"bibr11-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj995"},{"key":"bibr12-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.323"},{"key":"bibr13-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1080\/07420528.2018.1493596"},{"key":"bibr14-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.197"},{"key":"bibr15-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg702"},{"key":"bibr16-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"bibr17-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"bibr18-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"bibr19-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23638"},{"key":"bibr20-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282756"},{"key":"bibr21-1078155220988062","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.213"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220988062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220988062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220988062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:34Z","timestamp":1777688674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220988062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/1078155220988062"],"URL":"https:\/\/doi.org\/10.1177\/1078155220988062","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}